ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes
Physician's Weekly
JUNE 25, 2025
from the Velocity Clinical Research Center at Medical City Dallas, and colleagues conducted a phase 3 trial involving participants with type 2 diabetes treated only with diet and exercise, an HbA1c level of ≥7.0 Abstract/Full Text (subscription or payment may be required) More Information Copyright © 2025 HealthDay.
Let's personalize your content